Shares of Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) have been assigned an average recommendation of “Hold” from the thirteen brokerages that are currently covering the firm. One investment analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $15.56.
Several equities research analysts have recently issued reports on IRWD shares. BTIG Research reaffirmed a “buy” rating and issued a $18.00 price objective (up from $15.00) on shares of Ironwood Pharmaceuticals in a research note on Friday, September 23rd. Mizuho raised their price objective on Ironwood Pharmaceuticals from $16.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, July 15th. Zacks Investment Research raised Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a research note on Monday, July 25th. Barclays PLC raised their price target on Ironwood Pharmaceuticals from $11.00 to $12.00 and gave the stock an “equal weight” rating in a research note on Friday, August 5th. Finally, WallachBeth Capital raised their price target on Ironwood Pharmaceuticals from $15.00 to $17.00 and gave the stock a “hold” rating in a research note on Tuesday, September 27th.
Ironwood Pharmaceuticals (NASDAQ:IRWD) opened at 15.71 on Monday. The firm has a 50-day moving average price of $14.63 and a 200-day moving average price of $12.80. Ironwood Pharmaceuticals has a 52 week low of $7.35 and a 52 week high of $16.17. The stock’s market capitalization is $2.28 billion.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.01. The company earned $54.40 million during the quarter, compared to the consensus estimate of $54.49 million. Ironwood Pharmaceuticals had a negative net margin of 45.21% and a negative return on equity of 94.75%. Ironwood Pharmaceuticals’s revenue for the quarter was up 96.4% on a year-over-year basis. During the same period in the previous year, the business earned ($0.34) earnings per share. Equities research analysts predict that Ironwood Pharmaceuticals will post ($0.75) EPS for the current fiscal year.
In other Ironwood Pharmaceuticals news, Director Lawrence S. Olanoff sold 3,200 shares of the firm’s stock in a transaction on Tuesday, September 6th. The stock was sold at an average price of $13.72, for a total transaction of $43,904.00. Following the transaction, the director now directly owns 29,305 shares in the company, valued at approximately $402,064.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 7.17% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA increased its position in Ironwood Pharmaceuticals by 114.2% in the third quarter. BNP Paribas Arbitrage SA now owns 10,767 shares of the company’s stock valued at $171,000 after buying an additional 5,741 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in Ironwood Pharmaceuticals by 4.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 435,942 shares of the company’s stock valued at $5,700,000 after buying an additional 17,539 shares during the last quarter. Amalgamated Bank increased its position in Ironwood Pharmaceuticals by 3.0% in the second quarter. Amalgamated Bank now owns 13,668 shares of the company’s stock valued at $182,000 after buying an additional 397 shares during the last quarter. Teachers Retirement System of The State of Kentucky increased its position in Ironwood Pharmaceuticals by 3.2% in the second quarter. Teachers Retirement System of The State of Kentucky now owns 206,530 shares of the company’s stock valued at $2,701,000 after buying an additional 6,500 shares during the last quarter. Finally, A.R.T. Advisors LLC increased its position in Ironwood Pharmaceuticals by 53.2% in the second quarter. A.R.T. Advisors LLC now owns 304,215 shares of the company’s stock valued at $3,977,000 after buying an additional 105,600 shares during the last quarter. Institutional investors own 93.96% of the company’s stock.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company’s products Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders.
Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.